Zoomcar has announced the launch of Zoomcar Mobility Services (ZMS), to provide an array of software-based platform services across the entire spectrum of vehicle categories ranging from 2-wheelers, 3-wheelers, 4-wheelers, trucks, and buses. ZMS will work across both internal combustion and electric vehicles and is fully hardware agnostic. Read...
Read More“We developed and tested a multitude of approved workflows designed to unleash the full potential of xMED412’s outstanding physical properties and biocompatibility,” says Ken Kisner, Henkel’s head of innovation for 3D printing. “Nexa3D and Henkel have provided a digital manufacturing solution for a growing number of medical devices, athletic wearables, and personalized audio products. Read...
Read MoreGreg Moran, CEO & Co-Founder Zoomcar, states that with ZMS, fleet operators stand to reduce operating costs, improve safety and vehicle monetisation through features like real-time data analysis, and also improve customer engagement. One of ZMS’s key highlights is the proprietary driver scoring mechanism – an AI-powered algorithm with machine learning capabilities that tracks the real-time driving behaviour of the customer along with the present health of the vehicle. Read...
Read MoreZebra-Med’s AI1™ technology provides cloud-based analysis of images through FDA-cleared AI solutions, trained on millions of patient scans to triage acute medical conditions, detect incidental findings and stratify risk. This partnership with Canon Medical Systems USA, Inc. marks the introduction of Zebra-Med’s solution into the modality space, bringing AI analysis closer to the point of care. Read...
Read MoreSight’s use of machine vision has enabled the company to create a deep database of blood imagery that boasts more than half a petabyte of clinical image data. “This library of digitized blood samples is used not just to continue to perfect our AI engine, but also enables us to explore the diagnostic potential of our tech for early detection of serious health conditions like sepsis, cancer, and stroke,” Pollack noted. “While we are still in the early stages of R&D, we hope to be able to expand Sight OLO’s capabilities in the future with this new round of funding.” Read more...
Read More
